SCHEMBL6211409

SCHEMBL6211409

CC(C)(C)Oc1ccccc1OC[C]=O

nearest known ligand 0.34

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 3/20 0.33
POLB P06746 1/20 0.33
SMN1; SMN2 Q16637 1/20 0.33
RAB9A P51151 1/20 0.33
MAPT P10636 1/20 0.33
NPSR1 Q6W5P4 1/20 0.33
HSD17B10 Q99714 1/20 0.33
GLA P06280 1/20 0.33
SSTR1 P30872 1/20 0.33
SSTR4 P31391 1/20 0.33
KDM4E B2RXH2 4/20 0.33
ALDH1A1 P00352 3/20 0.33
GAA P10253 1/20 0.33
RXRA P19793 1/20 0.33
RXRB P28702 1/20 0.33
RXRG P48443 1/20 0.33
MTNR1A P48039 1/20 0.33
MTNR1B P49286 1/20 0.33
TDP1 Q9NUW8 1/20 0.32
KCNH2 Q12809 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6298723 0.84 KDM4E (0.41) L3MBTL1POLBSMN1; SMN2RAB9AMAPT
SCHEMBL514580 0.79 CA12 (0.54) L3MBTL1POLBSMN1; SMN2RAB9AHSD17B10
SCHEMBL10467741 0.79 L3MBTL1 (0.53) L3MBTL1MAPTNPSR1GLAALDH1A1
SCHEMBL5807025 0.78 ALDH1A1 (0.53) L3MBTL1SMN1; SMN2MAPTNPSR1HSD17B10
SCHEMBL29428931 0.77 CA1 (0.45) L3MBTL1HSD17B10KDM4EALDH1A1TDP1
SCHEMBL3820431 0.77 CA1 (0.45) L3MBTL1HSD17B10KDM4EALDH1A1TDP1
SCHEMBL11974099 0.76 ALDH1A1 (0.52) L3MBTL1RAB9AMAPTNPSR1GLA
Formaldehyde SCHEMBL28276257 0.75 CA1 (0.39) L3MBTL1SMN1; SMN2HSD17B10KDM4EALDH1A1
SCHEMBL16744336 0.75 PIM1 (0.36) L3MBTL1POLBSMN1; SMN2MAPTNPSR1
SCHEMBL96506 0.75 MEN1 (0.47) L3MBTL1POLBSMN1; SMN2RAB9AMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050256159-A1 1,4-disubstituted piperidine derivatives and their use as 11,betahsd1 inhibitors ASTRAZENECA AB (SE) 2005-11-17 US disclosed
EP-1556349-A1 1,4-DISUBSTITUTED PIPERIDINE DERIVATIVES AND THEIR USE AS 11-BETAHSD1 INHIBITORS Astrazeneca AB (SE) 2005-07-27 EP disclosed
WO-2004033427-A1 1,4-DISUBSTITUTED PIPERIDINE DERIVATIVES AND THEIR USE AS 11-BETAHSD1 INHIBITORS ASTRAZENECA AB (SE) 2004-04-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050256159-A1 1,4-disubstituted piperidine derivatives and their use as 11,betahsd1 inhibitors HSD11B1, HSD3B1, P4HA1 L3MBTL1 3461/4885POLB 1926/4885SMN1; SMN2 3573/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.